562 related articles for article (PubMed ID: 25683022)
1. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
[TBL] [Abstract][Full Text] [Related]
2. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
Kokabi N; Ludwig JM; Camacho JC; Xing M; Mittal PK; Kim HS
J Vasc Interv Radiol; 2015 Dec; 26(12):1777-86. PubMed ID: 26603497
[TBL] [Abstract][Full Text] [Related]
3. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
4. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
5. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
6. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
7. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
[TBL] [Abstract][Full Text] [Related]
8. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma.
Ou HY; Cheng YF; Chuang YH; Hsu HW; Chen CL; Lazo MZ; Weng CC; Yu CY; Tsang LL; Huang TL; Tong YS
Dig Dis Sci; 2020 Aug; 65(8):2433-2441. PubMed ID: 31732907
[TBL] [Abstract][Full Text] [Related]
10. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
12. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
13. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience.
Mannelli L; Kim S; Hajdu CH; Babb JS; Taouli B
Eur J Radiol; 2013 Apr; 82(4):577-82. PubMed ID: 23246330
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.
Sahin H; Harman M; Cinar C; Bozkaya H; Parildar M; Elmas N
J Vasc Interv Radiol; 2012 Feb; 23(2):241-7. PubMed ID: 22019180
[TBL] [Abstract][Full Text] [Related]
17. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the effect of transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with magnetic resonance diffusion-weighted imaging: 4-6-week follow-up of 25 cases].
Fan WJ; Zhang L; Ouyang YS
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2474-7. PubMed ID: 19080627
[TBL] [Abstract][Full Text] [Related]
19. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
[TBL] [Abstract][Full Text] [Related]
20. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization.
Dong S; Ye XD; Yuan Z; Xu LC; Xiao XS
Eur J Radiol; 2012 Mar; 81(3):472-7. PubMed ID: 21296517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
